HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on Prelude Therapeutics (NASDAQ:PRLD) but has lowered the price target from $17 to $6.
October 19, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Prelude Therapeutics' price target has been lowered from $17 to $6 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. indicates a potential decrease in the short-term value of Prelude Therapeutics' stock. However, the maintained 'Buy' rating suggests that the company is still viewed favorably by the analyst, which could mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100